awmsg logo



ranibizumab (Lucentis®)


Reference No. 3233


Appraisal information

ranibizumab (Lucentis®) 10 mg/ml solution for injection


Company: Novartis Pharmaceuticals UK Ltd
BNF category: Eye
NMG meeting date: 11/04/2018
AWMSG meeting date: 23/05/2018
   
   
Submission Type: Full Submission
Status: In progress
Advice No: Not available
Ratification by Welsh Government: Not available

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ratification by
Welsh Government

Indication

Treatment of visual impairment in adults due to choroidal neovascularisation not due to pathological myopia or wet age-related macular degeneration
Preliminary Appraisal Recommendation (PAR)
Download
Company Response to the Preliminary Appraisal Recommendation (CR PAR)
Download
AWMSG Secretariat Appraisal Report (ASAR)
Download